首页> 外文期刊>Endocrine Connections >Effects of combined growth hormone and testosterone treatments in a rat model of micropenis
【24h】

Effects of combined growth hormone and testosterone treatments in a rat model of micropenis

机译:生长激素和睾丸激素联合治疗对微阴茎大鼠模型的影响

获取原文
       

摘要

Although it is well known that penile growth is dependent on androgens, few clinical studies have reported successful treatment of micropenis with testosterone, likely due to concerns regarding the efficacy and safety of prolonged testosterone use. Thus, we assessed the synergenic effects of growth hormone (GH) treatments with and without testosterone on phallic growth in a rat model of micropenis. Fifty Sprague–Dawley rats were assigned to control (C), microphallus (MP), testosterone, GH (G) and GH plus testosterone (GT) treatment groups, and microphallus was induced by secondary hypogonadism. Pre-pubertal treatments with testosterone, GH or the combination were initiated from 7 days after birth and were maintained until 12 weeks of age. To assess the efficacy of treatments, phallic dimensions were determined and histological markers of cavernosal integrity were evaluated. Skeletal and gonadal safety profiles of the treatments were then assessed according to right tibial lengths and testicular weights, respectively. No monotreatments normalised penile dimensions, whereas combination treatments led to complete restoration. The combination treatment also prevented decreases in histological indicators of cavernosal integrity, including smooth muscle actin and collagen III expression levels and fat globule accumulation and sinusoidal density. These synergenic effects of GH treatments on penile growth may follow changes in androgen receptor expression levels and were accompanied by decreased testicular volume losses. Although the physiological conditions of phallic growth differ between humans and rats, this proof-of-concept study provides a strategy for circumventing the problems of testosterone monotherapy for human micropenis.
机译:尽管众所周知阴茎生长依赖于雄激素,但很少有临床研究报道用睾丸激素成功治疗微阴茎,这可能是由于担心长期使用睾丸激素的功效和安全性。因此,我们评估了有或没有睾丸激素的生长激素(GH)处理对微阴茎大鼠模型中阳具生长的协同作用。将五十只Sprague-Dawley大鼠分为对照组(C),微珠(MP),睾丸激素,GH(G)和GH加睾丸激素(GT)治疗组,并通过继发性腺功能减退症诱发微珠。从出生后7天开始使用睾丸激素,GH或其组合进行青春期前治疗,并一直维持到12周龄。为了评估治疗效果,确定了阴茎的尺寸并评估了海绵体完整性的组织学标志。然后分别根据右胫骨长度和睾丸重量评估治疗的骨骼和性腺安全性。没有单一疗法能使阴茎尺寸正常化,而联合疗法可导致完全恢复。联合治疗还可以防止海绵体完整性的组织学指标降低,包括平滑肌肌动蛋白和胶原III表达水平以及脂肪小球积聚和正弦密度。 GH处理对阴茎生长的这些协同作用可能跟随雄激素受体表达水平的变化,并伴有睾丸体积损失减少。尽管人与人之间的阴茎生长的生理条件有所不同,但这项概念验证研究提供了一种规避人类微阴茎睾丸激素单一疗法问题的策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号